This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain (RE-CONOCE)

Boehringer Ingelheim

Status: Completed

Conditions: Atrial Fibrillation

Treatments: Drug: NOAC

Study type: Observational

Funder types: Industry

Identifiers

NCT03285373

1160-0287

Details and patient eligibility

About

The primary objective of the study is to describe the usage of NOACs in patients with NVAF, in the hospital setting, based on the baseline characteristics at the time of first NOAC initiation.

Enrollment: 1,008 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient is willing and provides written informed consent to participate in this study
• The patient is at least 18 years of age
• The patient has a diagnosis of non-valvular atrial fibrillation (NVAF)
• The patient is on treatment with NOAC according to its approved local SmPC and has initiated his first NOAC starting from November 2016

Exclusion criteria

-if the current participating patient participate in any clinical trial of a drug or device will be excluded

Trial design

1,008 participants in 1 patient group

patients with NVAF

Description:

patients with Non Valvular Atrial Fibrillation

Treatment:

Drug: NOAC